Literature DB >> 8994325

Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re-infection and parenteral immunization.

N Cimolai1, A C Cheong, B J Morrison, G P Taylor.   

Abstract

Animal model studies of Mycoplasma pneumoniae infection after live respiratory challenge were conducted to investigate the issues of challenge-rechallenge associated accentuated pathology, postparenteral vaccination associated accentuated pathology, and oral vaccination. Live M. pneumoniae inocula were grown in hamster serum-based medium in order to reduce the potential for the serum growth component to participate in the hyperaccentuated histopathological response as seen with challenge-rechallenge experiments which have used horse serum-based growth media. Despite the use of homologous animal serum, an early hyperaccentuated response occurred (day 3 score 13.3 vs day 10 score 7.7; P = 0.02) which included perivascular infiltrates, and histopathological scores for early (day 3) and late (day 10) disease were similar (P > 0.10) between experiments of challenge-rechallenge when either homologous or heterologous sera were used in inoculum growth media. Parenteral vaccination with heat-killed bacteria also led to an early hyperaccentuated histopathological response after live respiratory challenge (scores on day 3: vaccinated 18.3, unvaccinated 6.2; P < 0.01) and this response was not significantly diminished when inocula were cleaned of growth medium components. An early accentuated response did not follow oral vaccination with heat-killed bacteria (score on day 3: vaccinated 5.7) and the late reaction was significantly less after challenge (scores on day 10: vaccinated 10.3, unvaccinated 14.6; P = 0.011). Studies of parenteral vaccination should include analyses for early disease after live challenge. Oral vaccination offers a promising route for stimulating protective immunity while minimizing undesirable recall immune events.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8994325     DOI: 10.1016/s0264-410x(96)00068-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Interferon gamma and interleukin 4 have contrasting effects on immunopathology and the development of protective adaptive immunity against mycoplasma respiratory disease.

Authors:  Sheetal Bodhankar; Xiangle Sun; Matthew D Woolard; Jerry W Simecka
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

2.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

3.  Mycoplasma bovis Membrane Protein MilA Is a Multifunctional Lipase with Novel Lipid and Glycosaminoglycan Binding Activity.

Authors:  Glenn Francis Browning; Kelly Anne Tivendale; James Yazah Adamu; Nadeeka Kumari Wawegama; Anna Kanci Condello; Marc Serge Marenda; Philip Francis Markham
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

4.  Vaccination of BALB/c mice with an avirulent Mycoplasma pneumoniae P30 mutant results in disease exacerbation upon challenge with a virulent strain.

Authors:  S M Szczepanek; S Majumder; E S Sheppard; X Liao; D Rood; E R Tulman; S Wyand; D C Krause; L K Silbart; S J Geary
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization.

Authors:  Sheetal Bodhankar; Mathew D Woolard; Xiangle Sun; Jerry W Simecka
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

Review 7.  Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development.

Authors:  Zhulin Jiang; Shuihong Li; Cuiming Zhu; Runjie Zhou; Polly H M Leung
Journal:  Pathogens       Date:  2021-01-25

8.  Defining protective epitopes for COVID-19 vaccination models.

Authors:  Nevio Cimolai
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

Review 9.  Non-primate animal models for pertussis: back to the drawing board?

Authors:  Nevio Cimolai
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-01       Impact factor: 4.813

Review 10.  Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2020-11-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.